SELLAS Life Sciences Group (SLS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group reiterated a Buy rating on the stock and has a $4.00 price target.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Jason McCarthy’s rating is based on the promising results from the Phase 2a trial for SELLAS Life Sciences Group’s SLS009, combined with Brukinsa, which showed significant efficacy in treating relapsed/refractory diffuse large B-cell lymphoma. The trial demonstrated a strong overall response rate, particularly in non-germinal cell B-cell-like disease, highlighting the potential of SLS009 in challenging hematological malignancies.
Furthermore, SELLAS has shown positive safety and efficacy signals in combining SLS009 with venetoclax and azacitidine in relapsed/refractory acute myeloid leukemia, indicating its potential to become a front-line treatment. This potential expansion of SLS009’s applicability, along with the anticipated updates and additional data expected in 2025, supports a positive outlook for the company. Additionally, recent financing activities have strengthened SELLAS’s financial position, allowing it to pursue important clinical milestones. These factors contribute to McCarthy’s optimistic Buy rating for SELLAS Life Sciences Group.
SLS’s price has also changed slightly for the past six months – from $1.310 to $1.310, which is a 0% increase.